Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Financial Statements and Exhibits

47

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

Exhibit No. Description

99.1 Press Release, dated October 11, 2017.


TITAN PHARMACEUTICALS INC Exhibit
EX-99.1 2 tv476840_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1     FIRST PATIENT TREATED WITH TITAN PHARMACEUTICALS’ SUBDERMAL IMPLANT FOR PARKINSON’S DISEASE   SOUTH SAN FRANCISCO,…
To view the full exhibit click here

About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

An ad to help with our costs